Pharmacologically active substance BPC, the process for its preparation and its use in the therapy

Abstract: A new substance BPC; the process for its preparation from human and animal gastric juice comprising purifications steps: centrifugalization, dialysis, ion-exchange, chromotagraphy, gal chromatography and lyophilisation; a drug for human and veterinary use and a process for the treatment of stress-induced diseases and disorders, inflammation and edemas, diseases and disorders of dopaminergic etiology, for treatment of diabetes mellitus, diseases and disorders of gastrointestinal tract, heart, kidney, pancreas, liver, testis, hematopoetic, skeletal and nervous, system, dementias, wound, burns, fracture, viral diseases, malignancy; in surgery; some disorders of fertility and immune system; protection against ionizing radiation; for veterinary use in commercial breeding.

Description: 1. Field of the Invention The present invention relates to new substance BPC, the process for its preparation from human or animal gastric juice and its use in the therapy. 2. Description of the Prior Art Gastric juice, considered as a secretion of the parietal as well as other cells, contains a number of electrolyte components, hydrochloric acid, a number of enzymes, namely, pepsin, other proteinases, renin, lipase, urease and lysozyme. There are also many other substances present in the juice of peptides and peptide fragments, e. g. peptide hormons gastrins, a highly potent gastric secretion stimulants, first discovered by J.S.Edkins, Proc.Roy.Soc.L., 76B , 376 (1905). In normal gastric juice are present glycoproteins (mucins), desribed by F.Hanrowitz, Chem. and Biology of Proteins, 1950, p.199., and Intrinsic Factor (IF), which is a thermolabile mucoprotein with M.W. about 60.000. This factor promotes vitamin B₁₂ absorption, Castle et al, Am.J.Med Sci. 178, 748 (1929). Till now, a substance having very strong antistress actions and other body-protective activities was not found in gastric juice. Description of the Invention Until now the gastrointestinal tract, especially stomach, was considered only as target organ of the stress. There was never discussed the possibility that the gastrointestinal tract, preferably the stomach, may be the organ which can initiate the defensive response of the whole organism. This response, actually directed against a stress, must be realized in the formation and release of a new endogenous agent. Our attempt was directed to isolate this agent from stomach juice. Finally we isolated the expected substance from the stomach juice of 542 patients. This substance was termed with abbreviation BPC which means: B ody P rotection C ompound. The structure of this substance is very complex and after our investigation until now can be characterized as folded protein with partial sequence from N-terminus: H₂N-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val- .... -COOH It has a molecular weight of about 40.000 ± 5.000 Daltons, determined by gel filtration. In the sense of the present patent application the agent BPC was prepared from human or animal gastric juice. This juice was first homogenized, centrifuged, the supernatant was purified by dialysis, ion-exchange chromatography, again by dialysis and lyophilisation and finally the agent BPC was obtained using gel-chromatography, dialysis and lyophilisation. Until now, no disclosure had been made anywhere. Moreover, this compound was never used as a medicament. The investigation of the biological actions of the BPC using many methods in vivo and in vitro shows: SURPRISINGLY BROAD SPECTRUM OF ACTIVITIES . But, it is known that many diseases and pathological states can awake by stress or on the other hand the trauma or disease can induce the stress by itself. These results also suggest that BPC is Produced by stress independent of its provenance. The agent BPC according to the invention was investigated in vitro and in vivo (rat, mouse, rabbit and guinea-pig) and the following pharmacological properties were found: 1. Acute toxicology Acute toxicology was determined in mice (18-25 g b.w.) (sacrifice after 30 days of experimental period) of both sexes, BPC was administered i.p., i.v. and i.g.. The lethal dose couldn't be obtained even with high dose such as 100 mg/kg b.w., which is at least 10³-10⁵ fold higher than minimal effective doses. In prolonged procedure, BPC was injected i.p., i.v., i.g. (30 mg/kg) once a day over 30 days. No pathological signs (morphological or physiological) were observed. In addition, the mean effective doses are from 0.01 to 50 ug/kg by i.p. administration and a therapeutic index (TI) of at least 1000. 2. Ulcer induced by water immersion or restraint stress Male rats (180-240 g) of Wistar strain were used. Animals were placed in water (26°C) for 3 hours or restrainted for 48 hours. After the end of experimental periods the stomach was investigated for the presence of a lesions ("stress ulcers"). BPC was injected i.p. and intragastrically (0.1 to 10 ug/kg) one hour or 24 hours before stress induction. A strong protective action of BPC was demonstrated on gastric lesions. 3. Ulcer induced by ligation of bile duct and hepatic artery or cysteamine administration The ligation-experiments were carried out on male rats (160-250g) of Wistar strain. The ligation of the bile duct and the hepatic artery was performed. This procedure induced ulcers of the stomach and duodenum in the intervals from 6-24 hours in addition to severe ischemic lesions of the stomach and duodenum. Likewise, cysteamine (400 mg/kg s.c.) was applied for induction of duodenal ulcer in female rats in 24 hours period. BPC was administered i.p. in doses from 0.1-10 ug/kg. The large ulcers induced by the described ligation in stomach and duodenum were strongly prevented in BPC treated animals. Likewise, the cysteamine-induced ulcers were also abolished by BPC pretreatment. 4. Effect on infarct induced on myocardium Male rats (180-230 g) of Wistar strain were immobilizated for 24 hours. The animals were then treated with indomethacin (25 mg/kg s.c.) at zero time of immobilization and 12 hours thereafter. BPC (50 µg/kg) was applied one hour before procedure and at 6 hours and 18 hours of restraint. A second group the animal were restrained for 48 hours. After these procedures the animals were sacrified and enzyme values were determined. A protective action of BPC was obtained. The protective effects were very impressive. In contrast, there was no protective effect against isoprenaline-induced heart lesions. Isoprenaline (30 mg/kg i.p.) was applied at zero time and 24 hours later. BPC (50 µg/kg, i.p.) was applied one hour before isoprenaline application. The animals were sacrificed 24 hours after the second isoprenaline administration. 5. Effect on arterial tension Male rats (180-220 g) anaesthetized by urethane were used. The carotid artery was canulated and the blood pressure was recorded on a dynograph. BPC was administered i.v. into v. jugularis in doses of 10 µg to 5mg/kg. The results showed no changes of arterial tension in animals in a group of rats prepared by above mentioned procedure. A short lasting changes of arterial tension were produced by i.v. administration of noradrenaline, adrenaline, 5-HT, acetylcholine or isoprenaline. The animals pretreated with BPC in doses of 10 ug to 5 mg/kg i.v. did not modify the change of arterial tension induced by used vasoactive substances. 6. Effect on damaged liver The experiments were carried out on male rats (180-250 g) of Wistar strain. The ligation of sole bile duct and of the hepatic artery was performed. This intervention induced severe ischemic necrotic lesions of liver's tissues in the intervals from 6 to 24 hours. BPC was administered i.p. in doses from 0.1 to 10 µg/kg. It strongly prevented (e.g. given 1 hour before ligation) or completely removed the injury (e.g. injected soon after ligation). In addition, the liver protective action of BPC administered i.p. in doses of 10 ug/kg of body weight one hour before intoxication of rats with carbon tetrachloride given in doses from 0.1-10 ml/kg i.g. or i.p. was demonstrated. BPC (0.01-10 ug/kg i.p./i.g.) prevented also the fatty liver changes induced by 48 hours restraint stress. 7. Effect on damaged pancreas Male rats (170-240 g) of the Wistar strain were used. The injury of pancreas was induced by ligation of the bile duct at its point of entry into duodenum. This procedure induced a marked pancreatic necrosis 24 hours later and about 50% of rats died within this experimental period. BPC administered in doses from 0.1 to 10 µg/kg i.p. produced a strong and dose dependent protective action. A significant beneficial effect on survival (ca. 82%) was demonstrated. 8. Effect on damaged kidney a. Unilateral nephrectomy Experiments were carried out on Wistar albino rats (190-250 gb.w.) of both sexes. Unilateral nephrectomy was performed. The increase of the remaining kidney weight was assessed in control and BPC group (10.0 µg/kg b.w. i.p. 1 hour before procedure) 24 hours after surgery. It was demonstrated that BPC strongly decreased the increased weight of the remaining kidney. Biochemical parameters were comparable in both groups. Therefore, it seems that BPC does improve the functions of the remaining renal tissue. b. Administration of gentamicin Experiments were carried out on the male Wistar rats. Damage of the tubules was produced by administration of gentamicin in dose 40 mg/kg i.p. (once a day) during 30 days. All the animals were sacrified 5 days after last treatment. In the control group of animals treated with gentamicin and saline damage of tubuli was found. In the BPC treated group the pathohistological manifestations were significantly smaller. 9. Effect on experimental diabetes mellitus Streptozocin or aloxan induced diabetes mellitus BPC in doses of 10 to 100 µg/kg i.p. tended to delay the streptozocin induced diabetes in male Wistar rats (175-230 g) induced. Moreover, BPC prolonged the animals survival time significantly. 10. Effect on the fever Antipyretic activity of BPC was investigated in male rats (180-220g) of Wistar strain, using injection of the brewer's yeast. The pretreatment with BPC, applied in single doses (5-20 µg/kg i.p.) one hour before injection of yeast significantly reduced the temperature increase calculated at 30 minute intervals for 3 hours at least. 11. Effect on carrageenin induced edemas The experimental edemas were induced in male mice (18-24 g) of both sexes by injections of carrageenin in the hind paws. BPC was effective in doses of 10 µg/kg i.p. when injected one hour before of experimental procedure reducing of the volume of panedema induced by mentioned agent. In addition, BPC in the same doses was inactive in the (53.5°C) hot plate test in mice unlike opioid agonists. 12. Effect on experimental rhinitis Wistar rats of both sexes were exposed to vapour of 10% formaldehyde one hour daily during 15 days. In the test group, BPC was administered in doses of 10 µg/kg i.p. on each day one hour before exposition. The animals were sacrificed after 13-15 days of treatment. In the BPC treated animals edema of the nasal mucosa were significantly smaller and epithelium was preserved in comparison with control group. Secretion was catarrhal and not purulent. 13. Effect on experimental fracture The influence of BPC (10 µg/kg, i.p.) on experimental fracture has been investigated on tibial fracture healing process in rats. With respect to controls, histologic examination showed a significantly increased healing rate in all rats treated subsequently with BPC. In addition, in these animals a markedly lower local haematoma was also registered than in control. 14. Effect on experimental burns The experimental procedure, burns of skin or of nasal mucosa, was carried out in mice (20-25 g). In comparison with control group (treated with saline) a purulent secretion was not observed and increased healing rate was consistently noted in all BPC pretreated (10 µg/kg, i.p., one hour before experimental procedure) animals. In addition, in animals with nasal injury, there was also only very modest posttraumatic swelling of the snout. Subsequently the normal nasal respiration was only slightly impaired and survival undisturbed. These results are obviously in contrast with the data obtained in the control group. 15. Effect on skin wounds The experimental procedure was carried out on rats (170-210 g) of Wistar strain. The skin wounds were produced by a large incision of the skin. BPC was administered i.p. in single dose of 10 µg/kg before incision. Unlike control group, lack of suppuration and edema, poor granulation formation and increased healing rate were consistently found in treated groups. 16. Neuropharmacological activity a) Neuropharmacological investigation according to Irwin demonstrated that BPC, even applied in dosage thousandfold higher than those proven to be of therapeutic effectiveness in many different models in mice (20.0 and 40.0 µg/kg b.w., i.p. or p.o.) did not induce any significant change in behavior in comparison with a control group. b) In the isolated heart of rat and rabbit, BPC applied in dose 30 µ/ml of Ringer-Locke solution did not induce any change in the intensity and frequency of contraction (preparation according to Langendorf). c) In the isolated ileum model (rat, guinea pig or rabbit) (preparation according to Magnus), BPC applied in the same dosage did not demonstrate any influence on the intestinal tonus, as well on contraction induced by acetylcholine, histamine and serotonin. 17. Effects of BPC on the delayed type hypersensitivity reaction (DTH) to DNFB The effect of BPC on a model of DTH reaction to DNFB on ears or paws on mice of NMRI strain. Animals which were pretreated with two sensitizing doses of DNFB have significantly thicker ears/paws compared to control animals. Mice pretreated with BPC i.p. in dose of 0.1 µg/10 g of body weight, one hour prior to the application of test dose of DNFB, had significantly smaller differences between treated and nontreated ear/paw. 18. Influence on pupil size In experiment with mice (18-22 g) of both sexes, BPC was instilled in left eye. The pupil size was measured by means of monocular lens. In addition, one group of animals was treated with BPC administered i.p. The results showed that BPC instilled topically did produce miosis. Also BPC injected i.p. provoked a pupil constriction of about 20%. This effect lasted at least 30 minutes. 19. The effect of BPC on the lesions of the colon The contact hypersensitivity in mice was induced with application of DNFB (2,4-dinitrofluorobenzene). Mice were treated with two sensitizing doses of 25 µl of 0.5% DNFB (in 4:1 acetone: olive oil) on the previously shaved skin of the abdominal wall in two subsequent days. 72 hours after the last sensitizing dose mice were treated with 20 ul of 0.2% DNFB, transrectally in aether anaesthesia. Animals were sacrificed 24 hours later and the colon was examined. Pathological changes in colon were characterized with severe haemorrhagies and ulcerations. These lesion occupied in some animals all parts of colon wall so that perforations can also occur. Application of BPC (0.1 µg/10 g) one hour after the DNFB challenge significantly decreased the incidence of lesions in colon. The most common lesion was petechial haemorrhagie. 20. Effects on the tumor cells a) Two cell lines L-924 and melanoma B-16 were cultivated in vitro under standard conditions. BPC was tested in vitro on its activity on growing of mentioned cell cultures. Two days following the initiation of the cell cultures, BPC was added in 3% and 0.3% concentration (0.1 ml). Three days later the numbers of cells per culture were determined by cell counter. The results showed that BPC has an inhibitory effect on both cell lines e.g. L-924 and melanoma B-16. b) Ehrlich's ascites tumor (EAT) is a tumor which can grow in all strains of mice. It can grow in ascitic or in solid form which depends upon a way of administration of tumor cells. We have tried to determine whether the incubation of EAT cells in BPC solution would change the survival time of mice after s.c. or i.p. injection of such treated EAT cells. We have observed the animals during the period of 45 days. Control of 15 NMRI male mice were injected with 0.4 x 10⁶Eat cells. Prior to the injection tumor cells were incubated for one hour at 4°C in saline. Volume of injection was 0.2 ml. The median survival time in this group of animals was 36 days, and only 3/15 animals survived 45 days. Experimental group of 15 NMRI male mice received the same dose of tumor cells in the same volume, but these tumor cells were previously incubated in BPC solution (2 µg/1 ml). Only 2/15 mice died during the observed period (45 days), the others survived more than 45 days. The difference between the control and the experimental group was statistically significant (p<0.01). If EAT cells were injected i.p. (instead s.c.) no difference between the groups was observed. It can be concluded that BPC prolonged survival of animals with tumors and that it possesses antitumor effect. 21. Influence on radiation induced injuries Experiments were carried out on mice (64) of both sexes, NMR-Y strain (22-28) g). The first control group (16 mice) was neither treated nor irradiated. The second control group (16 mice) pretreated with saline (0.2 ml) was irradiated with supralethal doses of 9 Gy (Co-60). Both experimental group (16+16) were irradiated with the same supralethal doses 9 Gy. One hour after irradiation to the first group BPC was administered in doses of 20 µg/kg b.w. However, the second group was treated with the same dose of BPC one hour before irradiation. BPC administered after irradiation has no influence on the survival of mice. However, BPC administered before irradiation increases survival rate after 12 days for 68,75% compared with other test group. 22. Influence on haematopoetic system Albino mice were given cytostatics (Endoxan, Vincristin, Adriablastin, Cytosin-arabinosid) at LD₅₀ dose i.p.. In the test group, BPC was given 1 hour before cytostatics in a dose 10 µg/kg, while the control group received only saline. The animals were sacrified on 3, 5, 7 and 11th day of experiment. Investigated were: blood (E,Hb,Htc,L,Tb, abs. number of neutrophiles), bone marrow, cytology and histology of liver and spleen. On the 3 st day of experiment there is no difference between experimental group regarding L,E,Tb and neutrophile values in comparison to control group. But in the bone marrow of BPC treated animals, the haemopoetic cells were still intact. In control animals aplasia is still present. In the 5th day of experiment significantly increases the number of neutrophiles and L until normalisation on 7th day of experiment. In control group the normalisation occurs much faster before 11th day of treatment. 23. BPC and fertility - influence on oligoasthenospermis The research was performed on ten consenting men, aged from 30 to 40 years with the diagnosis oligoasthenospermis. From these patients, ejaculate was taken after 3 to 4 days of abstinence. After liquefaction (30 min.) to the 0.5 ml of ejaculate is added layer of 0.5 ml of medium. The control medium consisted of HAM-F 10 with 10% of desactivated chordal serum. Experimental medium contained additionally 2 µg/ml or 4 µg/ml of BPC. After traveling time for 90 minutes at 37°C in atmosphere containing 5% of CO₂, in the Horwell Fertility Chamber was determined the number of progressive movable and immovable spermatozoa in 1 ml of ejaculate. Preliminary results show no effect on motility of spermatozoa in lower concentration of BPC. BPC in concentration of 4 µg/ml induced significantly higher % of motility in comparison with control group. 24. Effect of BPC on reproduction processes The effect of BPC on reproduction was investigated in mice with previous history of three pregnancies. Twenty days after cessation of the last lactation, the animals were subjected to copulation. BPC was applied in a dose 10 µg/kg i.p. once daily each day during the entire period of pregnancy (19-21 days) and lactation (next three weeks). Control group received simultaneously an equivolume of saline. The number of offsprings per female and the weight of offspring were daily recorded. A careful statistical analysis revealed consistently a significantly increased number of offsprings per female, as well as surprisingly no difference between their body weight at each studied time interval. All the female animals were allowed to recover for next 25 days after cessation of the lactation. Then, they were again subjected to copulation for investigating the effect on fifth pregnancy. When compared with the control group, an increased fertility rate with increased capability to lactation was observed in all BPC treated animals. It should be noted that no pathological changes as well as no changes in fertility rate were noted in BPC offsprings (regardless the number of maternal pregnancies). Therefore, it seems likely that BPC can improve the fertility rate even in quite old mice. For concluding, it is obvious that the obtained results are consistent with overall protective effect of BPC, as well as with the in vitro data obtained using human sperm. 25. The protective action BPDC on the periodontal tissues injury The aim of this research was to investigate the effect of BPC on the root resorption of the periodontal soft tissues induced by mechanical injury of the first molar of the albino rats. Thirty rats, 4 weeks old, were divided into a control group treated with saline and an experimental group treated with BPC. To produce mechanical injury we used needle like instrument (0.6 mm width and 1.9 mm in length) inserted to 1 mm in depth for 1 sec from the mesial gingival margin in an almot parallel direction to the mesial surface of the first maxillary right molar crown. The animals received the following treatment: Experimental group was treated after mechanical injury with solution of BPC (0.02 ml/200 g). The rats were divided in 12 groups and sacrified at interval of 1,3,5,6,14 or 21 days after the final treatment. The right maxillae of all control and experimental rats were removed, fixed in 10% neutral buffered formaline, demineralized with formic acid, embedded in paraffin and sectioned serially at 6 µm in a mesiodistal plane. The sections were stained with haematoxylin and eosin and examined with the light microscope. The histologic findings in the first molar of the rats from the control groups were: the presence of high number inflammatory cells was registered. A small resorption lacuna was observed between 1-3 days in part of the root surface at the alveolar crest level. At 5th day, the resorption lacuna extended in a coronal direction. The lacuna contained many odontoclasts. At 7th day, the resorption lacuna with many odontoclasts extended further coronally. At 14th and 21st day, the resorption lacuna still extended coronally, approaching part of the lacuna close to the cementoenamel junction. Experimental rats had all change similar between 1-5 days to the control animals, but there was no progression of root resorption between 14-21 day. In conclusion, it can be said that BPC elicited protective action against mechanical injury of periodontal tissues of molar of rats. 26. The influence of BPC on nucleus basalis and spinal cord lesion Dementia of the Alzheimer type (DAT) is characterized by an acquired global impairment of higher cortical functions which affect memory and cognition. Postmortem studies in patients with DAT have demonstrated that the nucleus basalis (NB) neurons undergo a profound and selective degeneration. These neurons are the major source of extrinsic cholinergic innervation to the cerebral cortex. The purpose of the present study was to investigate the influence of BPC on the passive avoidance behaviour in the rat with bilateral electrolytic lesions of the NB. Namely, rats with lesions of the NB may represent an experimental model of DAT. The study was carried out on albino rats. All groups of rats (with or without lesions of NB) were subjected to the passive avoidance test per the procedure of Ashford and Jones. The NB lesioned animals received saline solution (control group) or BPC solution 10 µg/kg i.p. (test group). The tested substances were injected: a) only once, immediately after the NB lesions were made, or b) once a day in the course of four consecutive days after the NB lesions were made. BPC was also administered once per day in the course of four training days, one hour before the passive avoidance experiment started. Each animal was subjected to the described behaviour test after a 20-day postoperative recovery period. Statistical significance was calculated according to the analysis of variance combined with Duncan's test for multiple comparisons (p<0.05). The resuls of investigation showed that: bilateral electrolytic lesions impair the passive avoidance in rats; BPC in used dosage doesn't influence the passive avoidance behaviour in intact, nonlesioned animals; BPC can improve the passive avoidance behaviour in the NB lesioned rats significantly. 27. Effect of BPC on the motor activity of rabbits with contusioned spinal cords The aim of this research was to investigate if BPC can modify the consequences of contusioned spinal cord. In present study adult rabits of both sexes were uses. A medial, dorsal L₁-L₆ laminectomy was performed under pentobarbital anaesthesia. By using the Technique of Albin et al, a measurable spinal cord compact injury was applied. The motor activity in the hind limbs was controlled in accordance with Tarlov's system once daily during nine days. Basically the ratings were as follows: 1) complete paraplegia, 2) minimal voluntary movements, 3) animal able to stand up, but unable to run, 4) animal able to run with some spasticity and incoordination, and 5) normal motor activity. Animals received saline in control group and BPC in doses of 10 µg/kg i.v. once per day during nine postsurgery days. Spinal cord trauma caused almost complete paraplegy. The average of complete (during nine posttraumatic days) tested motor activity in the animals receiving saline was 1.3 Tarlov's units (N=4). In animals receiving BPC it was 2.5 Tarlov's units (N=7). It is also evident that BPC improved motor activity of rabbits with spinal cord injury. From presented results it can be presumed that BPC can be a promising drug in the treatment of damaged neuron function (brain or spinal cord trauma) and that BPC should be given as early as possible after neurons damage. 28. Influence of BPC on intestinal motility, basal temperature and diuresis Application of BPC doesn't have any influence on diuresis, decreasing of basal temperature in vivo and on the contractility of intestinal smooth muscle of guinea pig in vitro. 29. Activity against Trichinella spiralis Application of BPC concentrate to experimental mice (D1) in doses of 10 µg/(kg b.w., i.p., previously infected with peroral administration of larvae Trichinella spiralis had the significant influence on survival of animals. 30. Commercial breeding 1419 healthy pigs (from total 4306 pigs) received BPC (10 µg/kg b.w., i.m.) immediately after birth, other 1440 at 13 th day of life, 1 day before castration, whereas remaining 1477 received only conventional Fe-therapy. Contusion, culling, mortality, body weight and food consumption were assessed after 4 weeks. BPC, applied only once significantly decreased culling rate (in the group treated with BPC immediately after birth) and contusion rate (in both groups treated with BPC). The same body weight was obtained in BPC treated animals with markedly lower consumption of food. Influence on infection: 40 weaned pigs infected with E.coli enterocolitis, 28 days old, were investigated. BPC was applied to 20 animals (10 µg/kg b.w. i.m.). One month later a significant lowering of mortality rate was noted in BPC treated animals. In another experiment, mortality rate after the first week of life was investigated in a total number of 1200 healthy pigs. 400 animals received BPC immediately after the birth, in addition to conventional Fe-therapy. A significantly lower mortality was noted in BPC (10 µg/kg b.w.,im.) treated animals. 31. Antiviral activity Antiviral activity was investigated in vitro and in vivo (mice). BPC was used in dose of 10 µg/kg b.w., i.p. or T.e.v. Remarkable activity was found against entero-viruses (Echo type: 6, 9, 11 and 16; Coxsackie type: A9, B3 and B4), CNS viruses (Ixode encephalities, LCM choriomeningitis) and ARBO viruses (Tahyna, Bhanja, and Calovo).Prolonged survival (72 hours to absolute survival) was noted in infected mice. In the following text some aspects of the invention will be described in other words: The technical problem The technical problem is determined whether it is possible or not to influence by pharmacotherapy with BPL the following diseases: 1. acute hepatitis (viral, drugs-induced, toxical, fulminant, regardless ehtiology); 2. chronic hepatitis; 3. liver cirrhosis; 4. cholestasis; 5. cholelelythiasis; 6. cholangitis; 7. liver transplatation - therapy before and after transplatation; 8. therapy before as well as after surgery also in other surgical liver operations (e.g. congenital malformations, benign and malignant bile duct stenosis); 9. prevention of pancreatic inflammation; 10. improvement of course of pancreatitis; 11. lowering of the frequency of postsurgical pancreatitis; 12. prevention of the complications and mortality from acute pancreatitis; 13. lowering the frequency of the chronic pancreatitis 14. acute haemorrhage in the uper gastrointestinal tract; 15. erosive gastritis; 16. acute ulcer, both gastric and duodenal ("stress ulcer"); 17. chronic peptic ulcer; 18. non-peptic ulcer of the gastrointenstinal tract; 19. shock (regardless etiology); 20. protection of the renal parenchyma from the development of the acute and chronic ischaemic and haemorrhagic necrosis; 21. acute and chronic renal failure, as well as all causes of renal failures; e 2: 22. skeletal trauma (fractures); 23. therapeutic operation on skeleton (osteotomy), 24. skeletal grafts (calems); 25. pseudoarthrosis; 26. arthrodesis; 27. wounds (increased healing rate, healing "per primam") 28. burns (skin and mucosal , increased healing rate) 29. anti-tumour activity; 30. antiinflammatory, antiedematous, antirheumatic activity; 31. antipyrrhetic activity; 32. rheumatic arthritis; 33. osteoarthrosis; 34. ankylosing spondilitis; 35. gonty arthritis; 36. extra-articular rheumatism (bursitis, tendinitis, synovitis; humeroscapular periarthritis) 37. inflammation and edema after surgical and non-surgical treatment, fracture and dislocation; 38. acute myocardial infarct; 39. myocarditis; 40. delay of the ischaemic changes in the tissues; 41. lower food consumption; 42. hyperprolactinemias; 43. M. Parkinsoni, parkinsonism; 44. glaucoma (increase of the intraocular pressure - dopamine and pilokarpine like activity); 45. diabetes mellitus; 46. barbiturate intoxication; 47. stress and all noxious events developing as the consequence of the stress The state of the technique There is still no a such total and specific pharmacotherapy, and the treatment of the complications is outside pharmacotherapy. The description of the solution of the technical problem Digestive tract and particularly stomach have been presently regarded only as stress-target organ. The possibility suggesting that the gastrointestinal tract, and specifically just stomach could be also the organ from which defensive body response may be initiated has not been so far considered. Substance initiating, mediating and controling the coping body response, latter called by us BPC, has been isolated by us from the gastric juice of 542 patients, as well as also from animals sources, by means of dialysis, ion-exchange filtration and gel-chromatography. Therefore, the substance BPC (although its structure is not completely clear) in different models of human diseases, both in vivo and in vitro. On basis of the obtained results, a successful application of extremely wide range could be expected in pharmacotherapy. The substance, isolated and called by us BPC, is so far unknown and thereby not applied in pharmacotherapy before. We have studied the obtained substance BPC on many different experimental species (e.g. rats, mice, guinea pigs) in vivo as well as in human cells in vitro. The substance BPC was called according to the abrevitation of the statement: " B ody P rotecting C ompound". Induction of the damages of the liver, pancreas, stomach and duodenum In the light aether anaestesea a median laparatomy has been done. Thereafter, bile duct has been ligated distally from duodenum, at the site where hepatic artery (by the same surgical maneuver simultaneously ligated together with bile duct) is arriving to it from the left side, a little below portal vein which remains undamaged above the ligature. Thereafter, the wound was tied, and the animals undisturbed since death or sacrifice. In a light aether anaesthesia, a median laparatomy was performed, and the bile duct was ligated just before its entry into the duodenum. The wound was thereafter tied, and the animals undisturbed since death or sacrifice. The animals were immersed in the water, temperature 26°C, 20 cm of the deep, during 3 hours. Immediately thereafter, they were sacrificed. 24 hours before water immersion, the animals were without food, with free access to water. In the light aether anaestesia, a median laparatomy was performed and the pylorus was ligated. The wound was tied, and the animals undisturbed since sacrifice only 15 minutes after pyloric ligation. The animals were immobilized for 24 hours. Indomethacin was applied simultaneously with immobilization and 12 hours latter. After 24 hours, the animals were sacrificed. Induction of the fracture, wounds, skin and mucosal burns Following light aether anaesthesia, a tibial fracture was induced by digital pressure using hipomochlion. The animals were sacrificed at days 5, 8, 9, 12 and 30 after fracture induction. Following light aether anaesthesia a large skin wound was performed. The animals were sacrificed each day during first five days, and thereafter after three days periods since 15 th day, as well as after the end of the five days periods since one month after wound induction. Following light aether anaesthesia, a burn was induced on the back of the animal (15x30 mm) by glowing thermocauter during 15 seconds. The animals were sacrificed at day 5, 9 and 30 after lesions induction. Following light aether anaesthesia, the nasal mucosa was burned bilaterally by glowing thermocauter during 5 seconds. The animals were sacrificed at day 5, 9, 30 after lesions induction. Induction of kidney damage Following light aether anaesthesia, a ligature of renal pedicle was done. The animals were sacrificed 24 hours latter. The wound was tied, and animals undisturbed since death or sacrifice. Induction of antiinflammatory, antiedemaous and antikpyrrhetic effect Carageenin (1%) was applied (0.05 ml s.c.) in the paw, as an inflammatory agent; volume of the paw was measured 3 hours latter using the standard procedure. For elevation of the body temperature the siccoferment was used (2,5 g/kg, i.p.). The temperature was thereafter measured rectally during 3 hours. Induction of the heart damage The animals were immobilized during 24 hours. Indomethacin was applied at the start of immobilization (0 hour), and 12 hours latter. After the end of 24 hours period, the animals were sacrificed. Isoprenaline (30.0 mg/kg i.p.) was applied at 0 and 24 hours, and after the end of 48-hour-period, the animals were sacrificed. Induction of CNS effects - the investigation of the effects on spontaneous behavior of the animals (mice) To establish the presence of dopamine neurons in the activity of the substance BPC in the CNS, a conventional dopamine agonist apomorphine (20 mg/kg s.c.) as well as serotonin (5 mg/kg i.p.) (comparative controls), or saline (0.9% NaCl) (control). The behavior of the animals after applications was investigated. The stereotypic behavior was assessed according to the method of Malick (1983). - the investigation of the effects on the iris muscle The investigated solution was applied: locally or intraperitoneally. The pupil diameter was measured in the suitable time intervals (5, 10, 15, 30, 60, 90 and 120 minutes) according to standard procedures. - the investigation of the effect on barbiturate depressive activity With Na-pentobarbital application (50 mg/kg i.v.) a narcosis was induced. The duration of barbiturate sleeping was assessed by the lack or presence of so called "righting reflex". The induction of the effects on diabetes mellitus Diabetes mellitus was induced by the application of alloxan (100 mg/kg i.p.) as well as streptozotocin (100 mg/kg i.p.). The glucose content in both urine and blood was measured according to standard procedures. The animals were undisturbed since death. The assessing of the effects Distribution The studies with I-125 marked BPC demonstrated the accumulation of BPC which is also dose and time depending, just in the stomach mostly, with distribution in the whole organism either after oral or parenteral application. Clinical observation In the studies dealing with damages of the liver, pancreas, stomach and duodenum, kidney, heart, fracture, wound, burns (skin, mucosal), diabetes mellitus, the general conditions of the BPC treated animals were significantly better than in control groups. Unlike control groups, in the treated groups, either no death or lower mortality rate were consistently observed. Macroscopical and pathological observations In the control animals with ligation of the bile duct and hepatic artery, a large yellow-green liver necrosis developed, sometimes involving also the whole hepatic lobules, as well as pancreatic necrosis and haemorrhagic lesions in the stomach and duodenum. The application of BPC successfully and dose-dependently prevented the above described lesions. In the control animals these lesions appeared as soon as 6 hours after ligation, whereas in the treated animals they were not visible even after 48 hours of ligation. Pathohistological examination supported the macroscopically observed changes. In the control animals with ligation of the bile duct at the site of its entry into duodenum, severe necrosis appeared in the pancreas as well as haemorrhagic lesions in stomach and duodenum. The administration of BPC dose-dependently prevented the development of the above described lesions. Pathohistological examination supported the macroscopically observed changes. In control animals subjected to water immersion stress, restraint stress plus indomethacin application, as well as short-time (15 min) pylorus ligation, we demonstrated the development of significant gastric lesions. The administration of BPC markedly decreased (or even completely abolished) the development of the gastric lesions following the above described noxious procedures. In control animals with ligature of renal pedicle we found severe lesions of the kidney. In BPC treated rats, the noted lesions were significantly lower. Pathohistological examination strongly supported the macroscopically observed changes and differences. In comparison with the control animals with tibial fracture, in the BPC treated animals the development of the posttraumatic haematoma was significantly less pronounced, with earlier functional use of the damaged leg. Qualitative pathohistological examination using conventional methods demonstrated increased and exaggerated rate of healing callus in the treated rats in the all observed periods. In control animals with wound, a large development of the seropurulent granulation was noted during the first days after injury induction. The BPC treated rats, unlike control group, was dry without exudation, with no visible granulations (per primam). Pathohistological examination supported the macroscopically observed changes and differences in all investigated periods. In control animals treated with restraint stress plus indomethacin, marked myocardial lesions were noted, with increased values of CPK in the serum. the administration of BPC significantly decreased the myocardial damages, and lowered the values of CPK. Pathohistological examination confirmed the macroscopically observed differences and changes. In the animals with experimentally induced diabetes mellitus, BPC abolished transitory glikosuria in the alloxan treated groups. In the animals treated with streptozotocin, the administration of BPC almost threefold increased the survival. In the all animals treated with BPC, polydipsia and polyphagia were less pronounced. Antiinflammatory, antiedematous, antipyrrhetic effect In animals treated with BPC a marked decrease of the carageenin-induced edema was noted relative to the control in all investigated periods. In animals treated with siccoferment, the administration of BPC significantly decreased the increased body temperature in comparison with the results noted in the control group. In vitro effects Two days after starting of cultivation of the human fibroblast L-929 and melanoma B-16 cells, BPC was added. Three days thereafter the number of cells was assessed by cell counter. BPC demonstrated a dose-dependent toxic effect on melanoma cells. No effect was demonstrated on fibroblasts. In comparison with control animals with skin burn, the treated animals exhibited a significant increase in the development of the crust. In control animals with mucosal burns (e.g. nasal mucosa) during first two days, a severe edema of the injuried tissue was noted, followed with seropurulent secretion, and partial functional obstruction of the nasal respiration. BPC treated animals showed no development of the above described changes. Pathohistological examination strongly confirmed the macroscopically observed differences and changes. Effects on the CNS The CNS effects of BPL were investigated by observing the behaviour of animals (mice). Five minutes after application, an increased locomotion was observed. The restlesness of the animals rised from minute to minute yielding its peak after 30 min. At that time, the animals stood on the hind legs, upright like a candle, and were sniffing. Straubs phenomenon was evident, the animals were running around the cage and a piloerection was also obvious. After apomorphine application the change apeared after 45 min, and was accompanied by a partial standing on the hind legs. After serotonin application, only a short period of sterotypical behaviour was noted (intensified locomotion, sniffing, cleaning with less intensity). Local aplication on the eye or i.p. injection resulted led to myosis (aproximately 20%). The application of BPC shortened the duration of barbiturate-induced sleep, which was established by shortening of the time without righting reflex (at least 60%). Effects on blood pressure, gut motility, basal temperature, diuresis The application of BPC had no effect on the changes of blood pressure induced by adrenaline, noradrenaline, isoprenaline, acetylcholine, and serotonin, nor on basal blood pressure values. The application of BPC shows no effect on gut smooth muscle motility in vitro (guinea pig). The application of BPC did not lower the basal temperature. The application of BPC did not lead to increased diuresis. Mechanism of action It can be supposed that the action of BPC, like other endogenous proteins, is a consequence of one of the following mechanism: direct interaction of the protein,or its fragments, with cell receptors; stimulation or inhibition of release of biologically active (stimulatory or inhibitory) proteins or non-proteins, through receptor or non-receptor linked mechanisms; interactions with enzymes which degrade endogenous biologically active peptides. Numerous protective effects on otherwise unrelated physiological entities could be explained if they are related to a common term - the stress (noxis) which they cause in the organism. So it seems likely that the substance BPC represents the primary coping response (starting from the stomach) on any stressfull event endangering the organism. Therefore the mechanism of BPC action represents the primary defense mechanism against different stressfull attacks (noxes). From the above it is concluded that it is possible to act, pharmacollogically, benefically on the course of the following disorders, by the application of BPC: I 1. acute hepatitis (virus induced, medicamentous, toxic, fulminant regardless the etiology); 2. chronic hepatitis 3. liver cirrhosis; 4. cholestasis 5. choledocholithiasis 6. cholangitis 7. liver transplantation-therapy before and after transplantation 8. preoperative and postoperative therapy in other liver surgery (e.g. congenital malformations, benign and malign stenosis of the choledochus) II 9. prevention of pancreatitis 10. amelioration of the course of pancreatitis 11. lowering of the rate of postsurgery pancreatitis 12. prevention of complications and mortality from acute pancreatitis 13. lowering of the incidence of chronic pancreatitis III 14. acute uper gastrointestinal tract bleeding 15. erosive gastritis 16. acute ulcers, gastric and duodenal (stress ulcers) 17. chronic peptic ulcers 18. non-peptic ulcers of the GI tract IV 19. shock (all etiology) V 20. protection of the renal parenchym against ishemic and haemorrhagic necrosis (acute and chronic) 21. acute and chronic renal failure as well as all coses of it VI 22. skeletal trauma (fractures) 23. therapeutic procedures on the skeletal system (osteotomia) 24. skeletal grafting 25. pseudoarthroses 26. arthrodesis 27. wounds (faster healing, healing per primam) 28. burns (skind, mucosa, faster healing) VII 29. antitomour effect VIII 30. antiinflamatory, antiedematous, antirheumatic effect 31. antipyretic effect 32. rheumatic arthritis 33. arthroses 34. ankylosing spondilitis 35. gout 36. extraarticular rheumatic disease (bursitis, tendinitis, sinovitis, humeroscapular periarthritis) 37. inflamation and oedema after surgical and neurosurgical procedures, accompaning fracture and dislocations XI 38. acute myocardial infarction 39. myocarditis 40. postponing of ischaemic tissue changes X 41. lowering of food intake (anorexic effect) XI 42. hyperprolactinaemia 43. Parkinson's disease XIII 44. glaucoma (lowering of intraocular pressure - dopamine and pilocarpine effect) XIV 45. diabetes mellitus XV 46. barbiturate intoxication XVI 47. stress and all stress-induced damages of the organism The application of the substance will be per os or parenterally, in the form of pills, capsules, tablets, lingualets, suppositories, vaginalets, injection sollutions, nasal spray, unguents, creams, gels, spray, eye drops, ear drops, nasal drops. Examples of technique: Example 1 : process of isolation of the BPC substance The material from which the substance was isolated was obtained from the gastric juice of 542 patients repeatedly and reproducibly, and from animal sources. The material was stored at 2°-8°C. The material is homogenised. Than it is centrifugated (12000 g /30 min.). After that the supernatant is collected. 200 ml of supernatant is dialysed in water (+4°C), 1:125, meaning until a conductability of 100µS is achieved. After that the dialysate is lyophilised. The dry rest is dissolved in 10ml of redestilled water and applied onto chromatographic column with a modiffied DEAE ion-exchange gel (40-80 um). The column is 25x250 mm. A buffer (Na acetate 0,01 M, pH 5,2) was used for dilution. Fraction detection was by an UV detector in the range of 2800 nm. The fractions of 40 - 120 ml were collected. The eluate was first concentrated by AQUACIDE - 3 (Calbiochem, USA) and than lyophilized. The dry substance is dissolwed in 10 ml 0,2 M phosphate buffer, pH 7,4 and than put on 2 chromatograph collumn with SEPHACRYL-S-200, (2,5x450mm) with a flow of 1,2ml/min. The fractions of 80 - 200 ml were collected. The solution is dialysed against distilled water, concentrated with AQUACID-3 and lyophilized. Approximatelly 200 mg of a dry, white substance is obtained. Characterization The BPC substance is characterized by IR an UV spectrum (Fig. 1 and 2). On the basis of the described pharmacological properties, the substance BPC can be used in the treatment of several diseases and disorders particularly when normal formation of this agent in organism is insufficient or even absent. It can also be used for the treatment of: a) All stress induced diseases and disorders. b) Circulatory disorders: Ulcer (different origins), shock (different etiology), Ischemia and infarcts (in different organs). c) Inflammation and edemas: Inflammation and edemas of all etiology, hepatitis (acute and chronic), liver cyrrhosis, cholangitis, pancreatitis (different etiology), gastroduodenitis, nephritis and nephropathias, myocarditis, pericarditis, endocarditis, arthrosis and arthritis, (different etiology), rhinitis, rheumatic disorders, disorders of joint of different etiology, fever, lesions induced by free radicals. d) Traumas and surgery: Traumatism (pre- and post-traumatic treatment), grafting, wounds, burns, fracture, post-surgery complications. e) Malignancy: some type of tumours; f) Diabetes mellitus; g) Disorders of dopaminergic or similar etiology: Obesity, M. Parkinsoni, hyperprolactinemias, glaucomas and barbiturate - induced narcosis (poisoning with barbiturates); h) Diseases and disorders of nervous system: Alzheimer's disease, ischemic and traumatic injuries of the nervous system and delay of senile degenerative changes; i) Dentistry: Diseases and disorders of oral mucosa, surgical treatment of peridontal pockets, inhibiton of roots resorption: j) Haematorpoetic system: Neutropenia, aplastic anemia, myelodysplastic syndrome transplantation of bone narrow; k) Injuries caused by radiation: Acute radiation syndrome and protection against radiation injuries; l) Immunology: Hypersensitive reactions, allergy and transplantations. m) Fertility: Increasing of fertility, therapy of oligoastenospermia and promotion of lactation; n) Veterinary use: In commercial breeding, decrease of mortality, stunting, contusion, improved conversion of food, increase of body weight; o) Antiviral therapy; p) Miscelaneous: Fatty change of liver, cholestasis, cholelithiasis, acute and chronic dysfunctions of kidney, toxic damage of kidney and liver Substance BPC will be used as a drug for enteral, local, rectal and parenteral administration. The pharmaceutical compositions are formulated by adding inorganic and organic adjuvants. For tablets and dragees there are added e.g. talc, lactose, starch, stearates etc. for solutions and suspensions there are added e.g. water, alcohols, glycerine etc. For suppositories there are added e.g. natural oils, hardened oils, waxes or polyethylene glycols. The formulations can generally contain suitable preservatives, buffers, stabilizers, surfactants, dissolving intermediaries sweetening agents and dye stuffs. A suitable daily doses for the substance BPC are from 5 to 50µg/kg of body weight and can be administered in single divided doses. Example 1) Preparation of the BPC from human gastric juice The raw material used for the preparation of the substance BPC was obtained reproducibly from stomach juice of 542 patients. The collected material must be stored between +2 and 8°C. It was homogenized before use. An aliquote part (200 ml) of this material was first separated by centrifugation (12000 G for 30 minutes) into crude parts and supernatant liquid. This liquid was dialysed against demineralized water (1:125) at +4°C until the conduction of 100 µS was attained. Then the solution was lyophilized. The dry residue was dissolved in 10 ml of distilled water and applied onto chromatographic column (25 x 250 mm) filled with DEAE-modified ion-cxchange gel (e.g. Trisacryl M-DEAE, R IBF). For elution was used sodium acetate buffer (0.01M, pH=5.2). Fractions were controlled with ultraviolett detector at 280nm. The fractions from the 40 th to 120 th ml of eluate were collected, concentrated using Aquacid-3 R (Calbiochem), then dialysed and lyophilized. The dry substance was dissolved in 10 ml of 0.2 M phosphate buffer (pH=7.4) and purified again on the chromatographic column (2.5 x 450 mm) filled with gel Sephacryl-S-200 R (Pharmacia Fine Chemicals). Flow was 1.2 ml/min. The fractions were collected from the 80 th to 200 th ml, dialysed against distilled water, concentrated using Aquacid-3 and then lyophilized. A 2,0 mg of white substance was obtained. The prepared substance - BPC - is very soluble in water. It decomposes between 180 and 200°C. Molecular weight, determined by gel chromatography is estimated to be 40.000 ± 5.000 Daltons. The ultraviolet spectrum (in water) shows absorption in regions as indicated in Fig. 1. The infrared spectrum (in KBr) shows absorption bands in regions as indicated in Fig. 2. The substance BPC has folded protein structure with partial amino acid sequence from N-terminus: H₂N-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val- .... -COOH Example 2. Preparation of the BPC from human gastric juice Homogenized human gastric juice of the same provenance as in example 1, was centrifuged, dialysed and lyophilised according to the procedure in example 1. The dry residue (80.4 mg) was dissolved in 0.1 M acetate buffer (3 ml, pH=5.22) and applied onto chromatographic column (10 x 50 mm) with ion-exchange resin Fractogel-TSK R (Merck) previously equilibrated with acetate buffer (pH=5.2). Flow was 0.7 ml/min. Fractions were controlled with UV spectromonitor at 280 nm. The first fraction with strong UV adsorbance was collected. This fraction was dialyzed against distilled water and then lyophilised (47 mg). This dry residue was dissolved again in acetate buffer (1 ml) and applied onto chromatographic column (16 x 560 mm) filled with gel Sephadex-G-100 R Pharmacia Fine Chemicals) previously equilibrated with acetate buffer. Flow was 0.3 ml/min. The collected fractions from 66 th to 108 th ml, were dialyzed against distilled water and lyophilised. A white powder was obtained which complies with product described in the previous example. Example 3. Preparation of the substance BPC from porcine gastric juice Homogenized porcine gastric juice (85 ml) was centrifuged, dialyzed and lyophilised according to the procedure described in previous example to obtain 440 mg of the dry residue. Then 110 mg of this dry residue was dissolved in 0.1 M acetate buffer (6 ml, pH=5.22) and applied onto chromatographic column (10 x 50 mm) filled with ion-exchange resin Fractogel-TSK and processed as described in previous example. A 44 mg of yellowish concentrate was obtained. A part of this concentrate (24 mg) was dissolved in 1 ml of the same acetate buffer and applied onto chromatographic column (16 x 565 mm) filled with gel Sephadex R -50/80, equilibrated with acetate buffer. The flow was 1.35 ml/min. Eluate between 65 th and 108 ml was collected, dialyzed against distilled water and lyophilised. The obtained white powder (10 mg) has (within the range of accuracy and reproducibility of analytical methods used) the same molecular weight and other properties as the product described in previous examples. Example 4. Tablets Composition mg/tablet substance BPC 0.3 lactose 37.7 starch 6.0 talcum 3.0 tragacanth 2.5 magnesium stearate 0.5 50 mg Example 5. Capsules Commposition mg/capsule substance BPC 0.3 lactose 99.0 magnesium stearate 0.7 100 mg Example 6. Lingualettes Composition mg/ling. substance BPC 0.3 mannitol 100.0 starch 5.0 polyvinyl pyrrolidone 1.5 talcum 3.2 110 mg Example 7. Suppositories Composition mg/supposit. substance BPC 0.5 polyethylene glycol 300 478.0 polyethylene glycol1500 529.0 polyethylene glycol 6000 38.0 emulsifier 14.5 1060 mg Example 8. Cream Composition gr/25 gr substance BPC 0.05 emulsifier 25.00 hydrogenated oleum arachid. 50.00 tween 60 120.00 propylen glycol 30.00 methylhydroxy benzoate 0.16 propylhydoxy benzoate 0.17 250 gr Example 9. Injection solution Composition mg/ml substance BPC 0.3 sodium carboxymethylcellulose 1.5 polyvinyl pyrrolidone 5.8 lecithin 2.7 benzuylalcohol 0.01 buffer q.s. bidistillated water ad 1 ml Example 10. Solution Composition g/25 ml substance BPC 0.05 glycerol 15.00 benzylalcohol 0.01 buffer q.s. bidistillated water ad 25 ml Example 11. Dry injection Composition weight (mg) substance BPC 0.3 mannitol 10.0 10.3 mg Example 12. Nasal spray Composition mg/each dosis substance BPC 0.5 benzylalcohol 0.15 uliglyol R -812 14.00 freon 12/114 60.00 74.65 mg Example 13. Drops for eyes, ears and nose Composition mg/5ml substance BPC 45 stabilisator 5 sodium hydrogenphosphate 116 sodium dihydrogenphosphate 33 benzalkonium chloride 0.5 bidistillated water ad 5 ml Example 14. Vaginalettes Composition mg/vaginal. substance BPC 0.3 polyethylene glycol 300 150.0 polyethylene glycol 1500 1290.0 polyethylene glycol 6000 700.0 propylen glycol 200.0 tween -40 59.7 lactose 100.0 2500 mg Example 15. Ophtalmic ointment composition mg/ 3.5 gr substance BPC 45 parrafine oil 1000 emulsifier 100 vaseline white 2355 3500 mg

Claims: The substance BPC characterized in regard to the process of its preparation having a molecular weight 40000 ± 5000 Dal., determined by gel chromatography, ultraviolet and infrared spectra as indicated in Fig.1 and 2, and partial N-terminal amino acid sequence: H₂N-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-....- COOH, said substance being obtainable by a process for preparation from humane or animale gastric juice having the follwoing production steps: (a) the collected and homogenized animal or human gastric juice is separated in crude parts and supernatant liquid by centrifugation; (b) the supernatant liquid is dialysed and lyophilized; (c) the dry residue is purified on the chromatographic column filled with weakly basic modified ion-exchange gel or resin; (d) the concentrate is again dialysed and lyophilized; (e) the dry residue is purified with gel chromatography and (f) the substance BPC is finally obtained from the concentrate using dialysis and lyophilisation. The process for the preparation of the substance of claim 1 comprising steps (a) to (f) as defined in claim 1 wherein in the step (c) DEAE, DMAE, QAE or with other basic group modified anion-exchange gel or resin is used. The process of claim 2, wherein in the step (e) is used an inorganic or organic gel with dextrane, polystyrene, polyacrylamide, agarose, polyvinyl or other matrix but having the fractionation capability in range of molecular weights between 20000 and 100.000 Daltons. Use of substance (BPC) as defined in claim 1 in the preparation of drugs for: a) All stress induced diseases and disorders; b) Circulatory disorders: Ulcer (different origins), shock (different etiology), Ischemia and infarcts (in different organs); c) Inflammation and edemas: Inflammation and edemas of alll etiology, hepatitis (acute and chronic), liver cirhosis, cholangitis, pancreatitis (different etiology), gastroduodenitis, nephritis and nephropathias, myocarditis, pericarditis, endocarditis, arthrosis and arthritis, (different etiology), rhinitis, rheumatical disorders-disorders of joint of different etiology,fever, lesions induced by free radicals; d) Traumas and surgery: Traumatism (pre- and post-traumatic treatment), grafting, wounds, burns, fracture, post-surgery complications; e) Malignancy: some type of tumors; f) Diabetes mellitus; g) Disorders of dopaminergic or similar etiology: Obesity, Parkinsoni disease, hyperprolactinemias, glaucomas and barbiturate induced sleep-time (poisoning with barbiturates); h) Diseases and disorders of nerve system: Alzheimer's disease, ischemic and traumatic injuries of the nervous system and delay of senile degenerative changes; i) Stomatology: Diseases and disorders of oral mucosa, surgical treatment of peridontal pockets, inhibiton of roots resorption; j) Haematopoetic system: Neutropenia, aplastic anemia, myelodysplastic syndrome transplantation of bone narrow; k) Injuries caused by radiation: Acute radiation syndrome and protection against radiation injuries; l) Immunology: Hypersensitive reactions, allergy and transplantations; m) Fertility: Increasing of fertility, therapy of oligoastenospermia and promotion of lactation; n) Veterinary use: In commercial breeding, decrease of mortality, stunting, contusion, improved food conversion, increase of body weight; o) Antiviral therapy; p) Miscelaneous: Fatty change of liver, cholestasis, cholelithiasis, acute and chronic dysfunctions of kidney, toxic damage of kidney and liver. A drug for the treatment of diseases and disorders according to the claim 5 comprising an active amount of the substance BPC as defined in Claim 1 in pharmaceutical form for enteral, peroral, parenteral, rectal and local administration.

Inventors: DUVNJAK MARKO MR SC, JUKIC JERKA DR, KRIZANAC SIMUN, MISE STJEPAN MR SC, PETEK MARIJAN MR SC, ROTKVIC IVO MR SC, SIKIRIC PREDRAG DR SC, SUCHANEK ERNEST DR SC, UDOVICIC IVAN DR, DUVNJAK, MARKO MR.SC., JUKIC, JERKA, DR., KRIZANAC, SIMUN, MISE, STJEPAN MR.SC., PETEK, MARIJAN MR.SC., ROTKVIC, IVO MR.SC., SIKIRIC, PREDRAG DR.SC., SUCHANEK, ERNEST, DR.SC., UDOVICIC, IVAN DR.
Applicants: DUVNJAK MARKO, JUKIC JERKA DR, KRIZANAC SIMUN, MISE STJEPAN MR SC, PETEK MARIJAN, ROTKVIC IVO, SIKIRIC PREDRAG, SUCHANEK ERNEST, UDOVICIC IVAN DR, DUVNJAK, MARKO MR.SC., JUKIC, JERKA, DR., KRIZANAC, SIMUN, MISE, STJEPAN MR.SC., PETEK, MARIJAN MR.SC., ROTKVIC, IVO MR.SC., SIKIRIC, PREDRAG DR.SC., SUCHANEK, ERNEST, DR.SC., UDOVICIC, IVAN DR.
Application year: 1990
Main classification: C07K1
IPC codes: A61K38, C07K14